Brian Toy, MD: Risk Factors for Uveitis
Investigators found that female sex, older age, and certain comorbidities were associated with an increased risk of uveitis.
Read More
Brian Toy, MD: Incidence of Uveitis in the US
Using a national medical claims database, investigators found the incidence and prevalence of uveitis in the US.
Dolly Chang, MD, PhD: Benefits of New Endpoints for Geographic Atrophy
Investigators calculated perilesional sensitivity and responding sensitivity for eyes in a geographic atrophy clinical trial and compared these to mean retinal sensitivity.
Dolly Chang, MD, PhD: Developing an Endpoint for Geographic Atrophy Research
Chang and colleagues are developing an outcome for geographic atrophy trials that measures vision loss rather than structural changes.
Sarah Hamm-Alvarez, PhD: Importance of a Tear-Based Parkinson Biomarker
A tear-based biomarker for Parkinson disease would allow providers to diagnose the condition sooner and create a measurement tool for new drug development.
Ronald Silverman, MD: Drawing Connections from the Eye to Preeclampsia
Investigators found significant differences in ocular flow velocity between patients with preeclampsia and without who had recently given birth.
Sarah Hamm-Alvarez, PhD: Developing a Biomarker for Parkinson Disease
Identifying a potential biomarker is an extended process, one which benefits from collaboration between researchers and clinicians of many specialties.
Ronald Silverman, MD: Preeclampsia & The Eye
The placenta plays a major role in preeclampsia but is difficult to access. Investigators have turned to the eye, the choroid in particular, looking for clues about this serious condition.
Low Follow-up Rates Among Homeless People Receiving Ophthalmology Referrals
People experiencing homelessness were more likely to follow-up on referrals from an ophthalmology clinic if they had finished high school or had a primary care provider.
Ziv-Aflibercept Comparable to Aflibercept, Ranibizumab
The ZEBRA study found that ziv-aflibercept was non-inferior to aflibercept and ranibizumab, and was more cost-effective.
Sarah Hamm-Alvarez, PhD: Comparing Basal & Reflex Tears
Investigators examined both basal and reflex tears from patients with and without Parkinson disease, in search of a potential biomarker.
Jennifer Lim, MD: The Impact of Artificial Intelligence in DR Screening
Investigator Lim sees hope that the EyeArt AI system will be able to screen more patients for diabetic retinopathy and help prevent blindness.
Sarah Hamm-Alvarez, PhD: Could Tears Hold a Parkinson Biomarker?
It’s difficult to diagnose Parkinson disease before some permanent neurological damage occurs. But tears may hold the key to earlier diagnoses.
Jennifer Lim, MD: Results of the EyeArt Diabetic Retinopathy Screening Study
The artificial intelligence system, EyeArt, was able to detect diabetic retinopathy with a sensitivity of 95.5% and specificity of 86%.
Jennifer Lim, MD: Training & Testing AI to Detect Diabetic Retinopathy
After training the EyeArt system on thousands of images of eyes with diabetic retinopathy, investigators tested the AI in a clinical trial.
Jennifer Lim, MD: Can AI Fill the Gap in Diabetic Retinopathy Screening?
With 8.5% of the global population having diabetes, there is a growing unmet need for diabetic retinopathy screening. Artificial intelligence may help close the gap.
Charles Wykoff, MD, PhD: Results & Implications of the PANORAMA Trial
Aflibercept not only significantly improved patients’ DRSS scores, but it also reduced vision-threatening complications by 75% compared to placebo.
Charles Wykoff, MD, PhD: PANORAMA Trial Design & Patients
The trial examined 2 doses of aflibercept versus sham in patients with good visual acuity and no center-involving diabetic macular edema.
Charles Wykoff, MD, PhD: Context of the PANORAMA Trial
PANORAMA is the first prospective study of high-risk patients with non-proliferative diabetic retinopathy, but not DME, in the anti-VEGF era.
FDA Approves Belimumab for Pediatric Lupus Treatment
The expanded indication allows the use of intravenous belimumab (Benlysta) in children as young as 5 years of age.
Richard Milani, MD: Addressing a Range of Digital Skills
With support from the “genius” at the O Bar, even patients without strong digital skills are able to participate in Ochsner’s digital medicine programs.
FDA Approves Combination Lotion for Plaque Psoriasis
The lotion, Duobrii, combines halobetasol propionate, a topical steroid, with tazarotene, a retinoid, to provide 2 mechanisms of action for treating plaque psoriasis.
Aimee Quirk: An Algorithm That Predicts Hospital Codes
Over a 90-day period, this algorithm reduced hospital codes, such as cardiac arrest, by 44%.
FDA Approves Risankizumab for Plaque Psoriasis
Risankizumab (Skyrizi) is now approved for treating moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
Richard Milani, MD: Connected MOM Program
The Connected MOM program allows self-monitoring during pregnancy so that some in-person visits can be skipped, and any issues can be identified early.
FDA Approves Non-Surgical Obesity Treatment Device
The TransPyloric Shuttle device is delivered endoscopically to the stomach and can be used for up to 12 months of treatment.
Phase 3 Trial of Ixekizumab Reports Positive Results
The COAST-X trial evaluated the safety and efficacy of ixekizumab for the treatment of non-radiographic axial spondyloarthritis (nr-axSpA).
20% of Children, Youth Drink No Water on a Given Day
Drinking no water on a given day was associated with greater caloric intake overall and a greater percentage of calories coming from sweetened beverages.
Richard Milani, MD: Digital Medicine Programs and the Ochsner O Bar
Richard Milani, MD, shares about the digital medicine program, particularly the track for patients with hypertension.
Aimee Quirk: What is innovationOchsner?
Aimee Quirk, CEO of innovationOchsner shares about how they have improved aspects of health care by introducing uses of technology.